BeiGene touts positive PhIII data on tislelizumab in aftermath of setbacks at FDA

Paul Schloesser

Associate Editor

After the FDA indefinitely delayed its decision on BeiGene’s Novartis-partnered PD-1 drug candidate tislelizumab as a monotherapy for esophageal cancer, Novartis announced that it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene touts positive PhIII data on tislelizumab in aftermath of setbacks at FDA

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

BeiGene touts pos­i­tive PhI­II da­ta on tislelizum­ab in af­ter­math of set­backs at FDA

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

BeiGene touts positive PhIII data on tislelizumab in aftermath of setbacks at FDA